Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats relapsed or refractory multiple myeloma. Sold as Elrexfio. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Elranatamab (sold as Elrexfio), first approved Aug 14, 2023, with 1 new use approved and 0 published complete response letters.
First approved in Japan 7 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Elrexfio S.C.Drugs with a new dosage indicated for the treatment of relapsed or refractory multiple myeloma (for use only if refractory or intolerant to standard therapies). · Pfizer Japan Inc. · Jun 24, 2025
Elrexfio S.C., new ingredientDrugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma (for use only if refractory or intolerant to… · Pfizer Japan Inc. · Mar 26, 2024
Safety Programs (REMS)
FDA requires these when a drug's risks need more than a label: training, enrollment or extra checks before it is prescribed or dispensed
Program
Updated
Elrexfio REMSRestricted: prescribers, pharmacies or patients must be certified or enrolled · Letters to doctors
Mar 25, 2026
Clinical Trials
50 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
